Viropro: Precisions on the Alpha Acquisition

VIROPRO (Pink Sheets: VPRO) On February 22nd, Viropro announced it had acquired Alpha Biologics Sdn of Penang Malaysia. In that Press Release, Viropro stated that the value of the plant would be reappraised to better reflect its true value; some investors were led to believe that Viropro would have to increase the number of shares issued as payment. Viropro therefore clarifies and confirms that its acquisition cost for the plant will remain at 525,000,000 shares whether or not value of the plan is reappraised.

Viropro also reemphasizes that it is currently processing all data pertaining to financial statements so as to disclose them as soon as possible and will from there undertake all necessary measures to regain full disclosure level. Rajiv Datar, CEO of Viropro, comments: “Income from our subsidiary in San Diego (Biologics Process Development Inc.) is increasing on a quarterly basis and it will show profits in 2011 so we are looking forward to producing explicit and detailed financials as soon as possible.”

Operations at the different units is going according to plan. Dr Datar further comments: “We’re quite pleased with the performance of our units. In Cambridge, UK for example, we recently reached an agreement with King’s College. This is a highly prestigious institution and we are extremely pleased to be serving them.”

Finally, Viropro announces it is deferring its shareholders meeting to June 17. Company requires more time to prepare the meeting considering the extent of the Agenda.

About Viropro, Inc.:

Viropro, Inc. conducts operations through its subsidiaries Viropro International Inc., and Biologics Process Development, Inc. and specializes in the transfer of its technologies for industrial production of biopharmaceutical therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. The Company’s principal objective is to provide its high-yield manufacturing process technology to biopharmaceutical companies in global markets with unmet medical and/or market needs. (www.viropro.com)

Viropro Inc. Safe Harbor Statement

Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.